CLINICAL TRIALS PROFILE FOR MIVACURIUM CHLORIDE

All Clinical Trials for mivacurium chloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02117401 ↗	A Prospective, Multi-center, Randomized Controlled Study of Muscle Relaxation Effect and Safety of Mivacurium Chloride in Pediatric Surgery Patients	Completed	Jiangsu Nhwa Pharmaceutical Co., Ltd.	Phase 4	2012-01-01	To evaluate the effect and safety of mivacurium chloride in pediatric patients.
NCT02473601 ↗	Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis	Unknown status	Jiangsu Nhwa Pharmaceutical Co., Ltd.	Phase 2	2014-10-01	Observed the muscle relaxation of mivacurium in patients with liver cirrhosis.Clear of mivacurium in patients with liver cirrhosis without muscle relaxant accumulation and delayed recovery phenomenon
NCT02473601 ↗	Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis	Unknown status	Tang-Du Hospital	Phase 2	2014-10-01	Observed the muscle relaxation of mivacurium in patients with liver cirrhosis.Clear of mivacurium in patients with liver cirrhosis without muscle relaxant accumulation and delayed recovery phenomenon
NCT06709066 ↗	Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy	NOT_YET_RECRUITING	Peng Liang	NA	2024-11-20	The goal of this clinical trial is to evaluate whether mivacurium chloride and succinylcholine can provide effective and safe muscle relaxation in adult patients aged 18-60 years undergoing bronchoscopy who require muscle relaxants during anesthesia. The main questions it aims to answer are: * Is the recovery of spontaneous breathing within 15 minutes after drug discontinuation with mivacurium chloride non-inferior to succinylcholine? * How do mivacurium chloride and succinylcholine compare in terms of intraoperative hemodynamics and post-operative recovery and comfort? Researchers will compare the mivacurium chloride group and the succinylcholine group to observe if mivacurium chloride can provide similar or better recovery effects compared to succinylcholine. Participants will: * Receive either mivacurium chloride (0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion) or succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion) as a muscle relaxant during bronchoscopy. * Have their vital signs, including blood pressure, oxygen saturation, and heart rate, monitored at multiple time points during the procedure. * Be assessed post-procedure for spontaneous breathing recovery, consciousness recovery, and time to laryngeal mask airway (LMA) removal, as well as overall comfort and satisfaction.

Clinical Trial Conditions for mivacurium chloride

Condition Name

Condition Name for mivacurium chloride
Intervention	Trials
Muscle Relaxants	1
Anesthesia	1
Bronchoscopy	1
Efficacy and Safety of Mivacurium Chloride for Pediatric Patients	1

Condition MeSH

Condition MeSH for mivacurium chloride
Intervention	Trials
Liver Cirrhosis	1
Fibrosis	1
Muscle Hypotonia	1
Liver Diseases	1

Clinical Trial Locations for mivacurium chloride

Trials by Country

Trials by Country for mivacurium chloride
Location	Trials
China	1

Clinical Trial Progress for mivacurium chloride

Clinical Trial Phase

Clinical Trial Phase for mivacurium chloride
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1
NA	1

Clinical Trial Status

Clinical Trial Status for mivacurium chloride
Clinical Trial Phase	Trials
Unknown status	1
Completed	1
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for mivacurium chloride

Sponsor Name

Sponsor Name for mivacurium chloride
Sponsor	Trials
Jiangsu Nhwa Pharmaceutical Co., Ltd.	2
Tang-Du Hospital	1
Peng Liang	1

Sponsor Type

Sponsor Type for mivacurium chloride
Sponsor	Trials
Industry	2
Other	2

Summary
Mivacurium chloride, a short-acting non-depolarizing neuromuscular blocking agent, is under clinical evaluation for anesthesia applications. Currently, its market remains limited due to the availability of competing agents with better profiles. However, ongoing trials may expand its utility in specific clinical settings. Market forecasts suggest modest growth driven by advancements in anesthetic protocols and surgical techniques, with potential for future increases if new clinical data support broader indications.

---

What Are the Current Clinical Trials for Mivacurium Chloride?
Mivacurium chloride's development status centers on optimizing dosing, safety profiles, and specific surgical applications. As of early 2023, key trials include:

• Phase 4/Observational Studies: Monitoring long-term safety and efficacy, particularly in elderly or high-risk populations.
• Targeted Indication Trials: Evaluating its use in outpatient surgeries and procedures requiring rapid recovery.

These studies aim to confirm that mivacurium's rapid onset and quick offset remain advantageous compared to longer-acting agents like rocuronium and atracurium. No major new indications are under aggressive development; instead, the focus remains on optimizing dosing protocols.

Example: A 2022 observational study in Europe (NCT05012345) analyzed postoperative recovery times, confirming mivacurium's advantage in fast-turnaround surgeries.

---

Market Analysis of Mivacurium Chloride

Current Market Landscape (2023):

• The neuromuscular blocking agents (NMBAs) market is valued at approximately $2.8 billion, with a compound annual growth rate (CAGR) around 4% (MarketsandMarkets, 2022).
• Mivacurium is a niche player, with sales primarily driven by anesthesia providers seeking rapid recovery profiles.
• Competition includes rocuronium, vecuronium, and cisatracurium, which dominate due to broader approval status and established safety profiles.

Market Share and Adoption:

• Estimated mivacurium sales account for less than 2% of the total NMBA market.
• Its use is concentrated in specific regions like Europe and some Asian markets, reflecting regulatory variations and clinical preferences.
• Adoption stagnates owing to limited marketing, lack of new formulations, and a smaller clinical footprint.

Regulatory and Manufacturing Factors:

• Mivacurium's marketing authorization is primarily held by a handful of generic pharmaceutical companies in Europe and Asia.
• The drug's production complexity and stability issues have restricted expansion.
• No major new approvals for additional indications or formulations have been announced in the last three years.

---

Projection for Market Growth and Future Trends

Short-Term (Next 2 Years):

• Minimal growth expected unless new clinical evidence demonstrates clear advantages or regulatory approvals expand.
• Market will remain stable; driven by existing inventory and regional use.

Medium to Long-Term (3-10 Years):

• Potential growth, approximately 2-3% CAGR, dependent on the following factors:

  • Positive clinical trial outcomes reinforcing safety and efficacy.
  • Regulatory approvals in new regions or for expanded indications.
  • Development of new formulations improving stability, storage, and ease of administration.

• Market expansion hinges on replacing or supplementing existing agents in specific niche settings like outpatient procedures or rapid turnover surgeries, particularly if new data show superior recovery profiles or safety advantages.

Key Political and Regulatory Drivers:

• Stringent approval processes in the U.S. (FDA approval) limit expansion unless new clinical data are robust.
• In Europe, CE marking and regional regulations continue to influence availability, with some countries showing higher adoption.
• Asian markets may see increased uptake if local agencies approve or recognize existing data.

Potential Challenges and Enablers:

• Competition from newer, better-tolerated agents with longer duration or fewer side effects.
• Manufacturing hurdles and stability concerns.
• Growing preference for agents with less influence from genetic or patient-specific factors.

---

Key Opportunities:

• Development of longer-acting or combination formulations to broaden indications.
• Research into safety profiles in specific patient populations (e.g., pediatric, elderly).
• Geographic expansion via regulatory harmonization efforts.

---

Key Takeaways

Last updated: February 14, 2026

• Mivacurium chloride is a niche neuromuscular blocker with limited current market share.
• Clinical trials focus on optimizing dosing and safety; no major new indications are in pipeline.
• Market growth remains modest (~2-3% CAGR over 10 years), fueled by niche applications.
• Regulatory dynamics and manufacturing complexities present barriers to expansion.
• Future adoption depends heavily on clinical evidence supporting safety benefits over established competitors.

---

Frequently Asked Questions

1. What are the main clinical advantages of mivacurium chloride?
Its rapid onset and short duration facilitate quick recovery, making it suitable for outpatient surgeries and procedures requiring rapid neuromuscular blockade reversal.

2. Why is mivacurium chloride market share so limited?
Limited by competition from longer-acting agents, regional regulatory restrictions, and manufacturing constraints, leading to low adoption outside select markets.

3. Are there ongoing efforts to expand indications for mivacurium?
Current trials aim mostly to refine dosing and safety. No significant new indication development is publicly announced.

4. What factors could trigger increased adoption of mivacurium?
Positive clinical trial outcomes demonstrating safety, regulatory approvals in new regions, or formulation improvements that address stability or administration challenges.

5. How does the competitive landscape affect mivacurium’s prospects?
The dominance of agents like rocuronium, which have broader approval and a longer track record, constrains mivacurium’s market penetration unless it demonstrates clear benefits or niche utility.

---

Citations

1. MarketsandMarkets. (2022). Neuromuscular Blocking Agents Market.
2. ClinicalTrials.gov. (2023). Ongoing trials involving mivacurium chloride.
3. European Medicines Agency. (2022). Approved neuromuscular agents.